Amy Schiffman, MD
Allergy & Immunology · Boca Raton, FLNPI 1972864064
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,425 of the $25,322 with a category attached, or 68.8%. AstraZeneca accounts for 79.8% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $6,471 and has fallen 58.9% since, to $2,658 in 2025.
Across 291 payments — averaging $87.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- GSK$710
- Takeda Pharmaceuticals U.S.A., Inc.$688
- Regeneron Healthcare Solutions, Inc.$575
- Amgen$502
- Alk-abello, Inc$360
- plus $2K from 23 others
What the payments were for
- Consulting fees$960%
- Speaking & faculty fees$17,42569%
- Travel & lodging$700%
- Food & beverage$7,63730%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 99 | $20,202 |
| GSK | 24 | $710 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $688 |
| Regeneron Healthcare Solutions, Inc. | 27 | $575 |
| Amgen | 19 | $502 |
| Alk-abello, Inc | 12 | $360 |
| Sanofi | 12 | $354 |
| CSL Behring | 9 | $260 |
| Blueprint Medicines Corporation | 3 | $232 |
| Genentech USA, Inc. | 6 | $232 |
| Novartis | 10 | $212 |
| Incyte Corporation | 3 | $166 |
| Pfizer | 6 | $119 |
| Biocryst US Sales Co., LLC | 1 | $117 |
| ADMA Biomanufacturing LLC | 2 | $96 |
| Pharming Healthcare, Inc. | 4 | $88 |
| Kaleo, Inc. | 4 | $87 |
| Grifols USA, LLC | 4 | $72 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| GC Biopharma USA, Inc. | 1 | $25 |
| LEO Pharma Inc. | 1 | $22 |
| Circassia Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,322 in reported general payments places this provider in the 85th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 25 | $92,585 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $46,956 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $43,526 |
| XolairOmalizumab | 13 | $36,773 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $15,582 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $13,537 |
| Arnuity ElliptaFluticasone Furoate | 23 | $8,461 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,581 |
| Epinephrine | 31 | $5,579 |
| BreynaBudesonide/Formoterol Fumarate | 23 | $5,364 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,492 |
| Ipratropium Bromide | 62 | $2,335 |
| Montelukast Sodium | 110 | $1,318 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,231 |
| Fluticasone Propionate | 13 | $672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $710 | $65,52594 claims |
| Grifols USA, LLCGamunex-C | $72 | $46,95612 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $20,202 | $22,16432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Boca Raton
- Robert SchrammBoca Raton$17K
- Charlene ShookoffBoca Raton$17K
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.